Huntsville-based Discovery Life Sciences has acquired the Gentest business unit of Corning Inc.
DLS says the acquisition will complement its acquisition last December of In Vitro ADMET Laboratories.
Together, the two acquisitions will help DLS strengthen “its ability to provide science-based biospecimen drug and biomarket development expertise.”
Announcing the acquisition, DLS said the combination creates “a unique innovation engine” to provide actionable results allowing customers to manage drug development programs efficiently and cost-effectively.
“We are excited to welcome the brilliant scientific experts and exceptional talent behind Corning’s Gentest portfolio to the Discovery team,” said Dr. Albert Li, chief scientific officer of pharmacology and toxicology at DLS. “Our combined decades of experience in the application of in vitro experimental approaches in the evaluation of drug metabolism, drug-drug interactions, toxicology, and pharmacology, plus our combined unparalleled technologies, allow Discovery to provide the most advanced and highest quality in vitro products and research services to the research communities and drug development laboratories.”
Discovery Life Sciences provides biospecimens for medical research.
